Journal Article
. 2002 Jan;(30).
doi: 10.1093/oxfordjournals.jncimonographs.a003463.

Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer

B Fisher 1 J H Jeong  J Dignam  S Anderson  E Mamounas  D L Wickerham  N Wolmark  
  • PMID: 11773294
  •     24 citations


Before 1989, credible information about the treatment of breast cancer was derived mainly from randomized clinical trials that enrolled women with either metastatic (stage IV); locally advanced (stage III); or primary, operable, axillary lymph node-positive (stage II) disease. This report provides information from six recent National Surgical Adjuvant Breast and Bowel Project (NSABP) trials involving lymph node-negative (stage I) patients. Findings from NSABP B-13 demonstrated, through 14 years of follow-up, improvements in disease-free survival (DFS) and overall survival from methotrexate and fluorouracil (MF), regardless of age, in women with estrogen receptor (ER)-negative tumors. Results from NSABP B-19, which was conducted with similar patients, demonstrated, through 8 years, a greater overall DFS and survival advantage with cyclophosphamide and MF (CMF) than that observed with MF. Findings from NSABP B-23, in which patients similar to those in B-13 and B-19 were randomly assigned to receive CMF plus placebo, CMF plus tamoxifen (TAM), doxorubicin (Adriamycin) and cyclophosphamide (AC) plus placebo, or AC plus TAM, demonstrated no difference in relapse-free survival (RFS) or overall survival among the four groups through 5 years, either for all patients or relative to age. NSABP B-14, which was carried out in women with ER-positive tumors, compared the outcomes of those who received either placebo or TAM. Through 14 years, superior DFS and overall survival advantages, as well as a reduction in contralateral breast cancer, were observed with TAM. No additional benefit resulted from TAM administration beyond 5 years. Findings from NSABP B-20, a second study conducted in patients with ER-positive tumors, showed, after 8 years, both a DFS and an overall survival advantage from TAM plus either MF or CMF over that achieved with TAM alone. A recent meta-analysis in women with negative lymph nodes and either ER-negative or ER-positive tumors of less than or equal to 1 cm in size was conducted using patients from five NSABP trials. After 8 years, the RFS in women with ER-negative tumors was greater in the group treated with surgery and chemotherapy than in those who underwent surgery alone. In women with ER-positive tumors, RFS and overall survival advantages were observed from the addition of chemotherapy to TAM when that treatment regimen was compared with TAM alone. In addition, evidence has been presented from NSABP B-21, a trial evaluating radiation therapy (XRT) and/or TAM for the prevention of ipsilateral breast tumor recurrence (IBTR) after lumpectomy in women with tumors less than or equal to 1 cm. Findings have shown that XRT is superior to TAM and that XRT + TAM is superior to XRT alone for preventing IBTR. The findings demonstrate that chemotherapy and/or hormonal therapy is effective for the management of women with negative axillary lymph nodes and either ER-negative or ER-positive tumors. Because it also has been proven effective in women with tumors less than or equal to 1 cm, such therapy might also be considered in the treatment of that patient population.

Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer.
Xianglin L Du, Charles R Key, +2 authors, James S Goodwin.
Ann Intern Med, 2003 Jan 17; 138(2). PMID: 12529090    Free PMC article.
NSABP breast cancer clinical trials: recent results and future directions.
Eleftherios P Mamounas.
Clin Med Res, 2005 Jun 03; 1(4). PMID: 15931325    Free PMC article.
Tumour dormancy in breast cancer: an update.
Muriel Brackstone, Jason L Townson, Ann F Chambers.
Breast Cancer Res, 2007 Jun 15; 9(3). PMID: 17561992    Free PMC article.
Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells.
Marie Maynadier, Philippe Nirdé, +4 authors, Marcel Garcia.
Adv Exp Med Biol, 2008 May 24; 617. PMID: 18497073    Free PMC article.
Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1.
Hans Neubauer, Susan E Clare, +9 authors, Michael A Cahill.
Breast Cancer Res, 2008 Oct 17; 10(5). PMID: 18922159    Free PMC article.
Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.
Douglas T Ross, Chung-Yeul Kim, +7 authors, Norman Wolmark.
Clin Cancer Res, 2008 Oct 18; 14(20). PMID: 18927301    Free PMC article.
Gene expression profiling of breast cancer.
Ting Bao, Nancy E Davidson.
Adv Surg, 2008 Oct 29; 42. PMID: 18953822    Free PMC article.
Chemotherapy use for hormone receptor-positive, lymph node-negative breast cancer.
Michael J Hassett, Melissa E Hughes, +7 authors, Jane C Weeks.
J Clin Oncol, 2008 Oct 29; 26(34). PMID: 18955448    Free PMC article.
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
Catherine Oakman, Silvia Bessi, +3 authors, Angelo Di Leo.
Breast Cancer Res, 2009 May 14; 11(2). PMID: 19435470    Free PMC article.
BMI1 cooperates with H-RAS to induce an aggressive breast cancer phenotype with brain metastases.
M J Hoenerhoff, I Chu, +4 authors, J E Green.
Oncogene, 2009 Jun 23; 28(34). PMID: 19543317    Free PMC article.
Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells.
Michele I Vitolo, Michele B Weiss, +6 authors, Kurtis E Bachman.
Cancer Res, 2009 Oct 22; 69(21). PMID: 19843859    Free PMC article.
ATBF1 inhibits estrogen receptor (ER) function by selectively competing with AIB1 for binding to the ER in ER-positive breast cancer cells.
Xue-Yuan Dong, Xiaodong Sun, +4 authors, Jin-Tang Dong.
J Biol Chem, 2010 Aug 20; 285(43). PMID: 20720010    Free PMC article.
Synthetic lethal approaches to breast cancer therapy.
Farah L Rehman, Christopher J Lord, Alan Ashworth.
Nat Rev Clin Oncol, 2010 Oct 20; 7(12). PMID: 20956981
Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence.
Mary Jo Fackler, Christopher B Umbricht, +13 authors, Saraswati Sukumar.
Cancer Res, 2011 Aug 10; 71(19). PMID: 21825015    Free PMC article.
Highly Cited.
When Palliative Treatment Achieves More Than Palliation: Instances of Long-term Survival after Palliative Radiotherapy.
Madhup Rastogi, Swaroop Revannasiddaiah, +3 authors, Manish Gupta.
Indian J Palliat Care, 2012 Oct 25; 18(2). PMID: 23093827    Free PMC article.
Neurotrophic effects of neudesin in the central nervous system.
Ikuo Kimura, Yoshiaki Nakayama, +2 authors, Nobuyuki Itoh.
Front Neurosci, 2013 Jun 28; 7. PMID: 23805070    Free PMC article.
Heterogeneity of circulating epithelial tumour cells from individual patients with respect to expression profiles and clonal growth (sphere formation) in breast cancer.
M Pizon, D Zimon, +3 authors, O Camara.
Ecancermedicalscience, 2013 Aug 29; 7. PMID: 23983815    Free PMC article.
The importance of systemic therapy in minimizing local recurrence after breast-conserving surgery: the NSABP experience.
Eleftherios P Mamounas, Gong Tang, Qing Liu.
J Surg Oncol, 2014 Apr 15; 110(1). PMID: 24729388    Free PMC article.
A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumor modulates late recurrence in breast cancer independent of disease subtype.
Qing Cheng, Jeffrey T Chang, +4 authors, H Kim Lyerly.
Breast Cancer Res, 2014 Jul 26; 16(4). PMID: 25060555    Free PMC article.
Long term side effects of adjuvant chemotherapy in patients with early breast cancer.
Jessica J Tao, Kala Visvanathan, Antonio C Wolff.
Breast, 2015 Aug 25; 24 Suppl 2. PMID: 26299406    Free PMC article.
The Globalization of Cooperative Groups.
Manuel Valdivieso, Benjamin W Corn, +8 authors, Charles D Blanke.
Semin Oncol, 2015 Oct 05; 42(5). PMID: 26433551    Free PMC article.
Impact of chemotherapy relative dose intensity on cause-specific and overall survival for stage I-III breast cancer: ER+/PR+, HER2- vs. triple-negative.
Lu Zhang, Qingzhao Yu, +5 authors, Tekeda Ferguson.
Breast Cancer Res Treat, 2018 Jan 26; 169(1). PMID: 29368311    Free PMC article.
The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Napat Saigosoom, Doonyapat Sa-Nguanraksa, +2 authors, Pornchai O-Charoenrat.
Cancer Manag Res, 2020 Apr 21; 12. PMID: 32308485    Free PMC article.
Hierarchical clustering of activated proteins in the PI3K and MAPK pathways in ER-positive, HER2-negative breast cancer with potential therapeutic consequences.
Dinja T Kruger, Karin J Beelen, +4 authors, Sabine C Linn.
Br J Cancer, 2018 Oct 06; 119(7). PMID: 30287915    Free PMC article.